High-Concentration Formulation
From early research to late-phase development, our experts design robust high-concentration formulations optimized for seamless manufacturing, commercial stability, and patient-centric administration. Coriolis Pharma specializes in overcoming the critical biophysical challenges of high-density drug products—effectively managing high viscosity, controlling aggregation, and ensuring long-term stability to enable successful subcutaneous injection.
High-Concentration Formulation for Modern Modalities
Whether your program requires liquid formulation development/optimization or complex stabilization, Coriolis Pharma delivers tailored formulation strategies across diverse molecular formats:
Navigating the Complexities of High-Concentration Formulations
Biotherapeutic innovators face severe, multi-faceted technical roadblocks when pushing concentration boundaries to meet market demands. We help you proactively solve your most critical challenges:
- Meeting the rapidly rising demand for home-care administration and subcutaneous delivery routes.
- Balancing high concentration targets with critical product parameters like long-term stability and viscosity / injectability.
- Selecting the right primary container closure system while ensuring complete material compatibility.
- Avoiding catastrophic late-phase failures, unanticipated technical problems, and massive project expenses.
High-Concentration Feasibility Assessment
Coriolis Pharma establishes a rigorous, data-driven foundation for your HCLF program using minimal drug substance material—scaling seamlessly from simple platform formulations up to advanced custom formulation designs.
-
We analyze the 3D structure of your molecule to map protonation curves and predict the isoelectric point, the molecule’s inherent susceptibility to self-association, high viscosity, deamidation, isomerization, and oxidation. In addition, we suggest formulation parameters suitable for a high-concentration formulation.
-
We conduct specialized wet-lab testing to characterize thermal, colloidal, and conformational stability, alongside self-interaction tendencies, unspecific binding, and hydrophobicity.
-
We actively evaluate the real-time physical behaviour of the molecule during concentration to pinpoint exact viscosity limitations and maximum concentration limits
Custom Development & Verification Pathway
Once initial feasibility parameters are set, Coriolis Pharma does not stop there. We use this data to select the ideal, phase-appropriate development route tailored specifically to your molecule’s unique profile, systematically moving it from early candidate to a robust, clinic-ready drug product. Our comprehensive development capabilities include:
High-Throughput Screening (HTS)
Rapid screening of formulation conditions either for broad screening purposes of many conditions or focused on neutralizing molecular specific “red flags” (e.g., targeted viscosity reduction or mitigation of self-association).
Short-Term Stability & Stress Studies
Evaluating early-stage formulation stability under accelerated and stress conditions within the intended primary packaging.
Container Closure Selection & Compatibility
Testing and selecting the optimal syringe, vial, or cartridge system to prevent surface adsorption, leachable interaction, or mechanical failure.
Long-Term Stability Studies
Executing full ICH-compliant stability programs in the final primary packaging to guarantee compatibility and commercial shelf-life
In-Use Studies
Simulating real-world clinical handling, preparation, and administration (e.g., hold-time studies, syringeability, dose accuracy) to ensure patient safety.
Comprehensive Biotherapeutic Expertise
Our deep-rooted academic background, drug development and commercialization expertise keep us at the cutting edge of formulation science and analytical method development. This expertise enables us to support a wide range of modalities.
High-Concentration Formulations Frequently Asked Questions (FAQs)
-
We provide full lifecycle support from discovery and preclinical screening through early and late-phase development (Phase I–III) to commercial services. By embedding data-driven strategies early, we ensure your high-concentration liquid formulations (HCLFs) scale seamlessly from the lab to the market.
-
We integrate phase-appropriate analytics to manage high-density matrices. Our services cover method development, validation, and verification for proteins, peptides, and oligos, alongside advanced particle characterization for regulatory compliance. We also provide fast-track analytics and complete release testing and tech transfer support.
-
We de-risk scale-up by providing advanced characterization support for process development and process characterization studies, tracking critical quality attributes (CQAs) beyond standard release testing, and offer small-scale models of important unit operations (e.g. mixing, pumping, filtration, filling, hold-time, and material compatibility studies). We can support comparability studies following manufacturing process or site changes. If particle issues arise on the production floor, we provide rapid manufacturing troubleshooting (particle ID services). Our expertise also includes high–concentration lyophilization process development, optimization and transfer.
High-Concentration Formulations Resources
Articles
Concentration Feasibility in High Concentration Formulation: A Q&A with Eva Keilhauer
July 28, 2026
Articles
Optimizing Biologics Development: A Technical Blueprint for Commercial Success
May 12, 2026
Publications
April 30, 2026
Talk to Our Experts or Request a Quote
Our expert team is ready to answer your questions and guide you to the services best suited to your program’s modality, stage and challenge. If your needs are well-defined, we’ll begin the quotation process.
INFOGRAPHIC
Driving Success from Preclinical to Commercial Approval & Beyond
A guide for early and late-stage development, commercialization, and lifecycle management
Learn More
